Loading
The gap after a transplant is not that nobody knows what should be checked, it is that no mechanism tells an individual survivor what is due. This trial tests an organised four-step late-effects service against usual care.
The transplant facet of this corpus names the problem this trial attacks: there is a published list of what should be done, an inspected standard for the programmes that should do it, and registries that record outcomes, and there is no mechanism that reliably tells an individual survivor which tests they are due this year.
AlloCare is a two-arm randomised trial of a stepped-care multimodal intervention with four steps: screening for vulnerability, digital health support and education, individual consultations based on patient-reported outcome data using the HM-PRO instrument, and multidisciplinary late-effects management driven by that assessment. The control arm receives usual care. The trial has an internal pilot phase.
The primary endpoint is the between-group change in the EORTC QLQ-C30 summary score from baseline at three months after transplant to the end of the intervention at twelve months, with follow-up at eighteen months. One hundred participants at a single centre is small, and the result will be a signal about whether an organised service changes quality of life rather than a definitive answer about which components did it. It is included here because trials of the service rather than of an intervention are rare, and because the design is one a health system could copy.
The registry records no phase for this study, as it tests a service rather than a drug; it is filed here as phase 3 because OnCo's schema has no value for an unphased randomised trial. Registry dates, read on 2 October 2026: start 1 November 2024 (actual), primary completion 1 October 2027 (estimated), completion 1 December 2027 (estimated). Enrolment of 100 is the registry's estimate.
Shares Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Late effects after a stem cell transplant, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant.
Shares Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Late effects after a stem cell transplant, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant.
Shares Quality of life after transplant and cell therapy, Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Late effects after a stem cell transplant, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant, follow-up.
Shares Nobody owns the follow-up once the oncology clinic lets go, Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship.
Shares Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Late effects after a stem cell transplant, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant.
Shares Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Late effects after a stem cell transplant, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant.
Shares Nobody owns the follow-up once the oncology clinic lets go, Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant.
Shares Quality of life after transplant and cell therapy, Late effects after a stem cell transplant, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, transplant.